Nausea affects roughly 24–33% of people, diarrhea 19–23%, constipation 16–17% and vomiting 8–12%. Effects cluster in the days after a dose increase and usually settle within one to two weeks at each new dose. Constipation is the one that tends to persist.
On this page
What the trials found
In SURMOUNT-1, gastrointestinal effects were the dominant adverse events across all three doses and were mostly mild to moderate. Discontinuation because of adverse events ranged from 4.3% to 7.1% — meaning more than nine in ten participants tolerated the drug well enough to continue.
Compared with semaglutide, tirzepatide tends to produce somewhat more constipation and somewhat less nausea at equivalent efficacy — a pattern often attributed to GIP receptor effects on gut motility and central nausea signaling.
Nausea: what works
Eat smaller portions and stop at the first sign of fullness rather than finishing the plate. Lower-fat, blander food is tolerated better in the 48 hours after an injection. Cold foods often go down easier than hot ones because they carry less aroma.
Timing your injection for an evening before a quieter day lets you sleep through the worst window. If nausea is severe at a new dose, ask your prescriber about staying at the previous dose for an extra four weeks — a slower ladder is almost always better than quitting.
Constipation: the persistent one
Increase fiber gradually rather than all at once, hydrate deliberately, and move daily. Ask your prescriber before adding a stool softener or an osmotic laxative. Unlike nausea, constipation frequently persists for months rather than weeks, so build a routine you can maintain.
Red flags — stop and call a clinician
Severe, persistent abdominal pain radiating to the back, with or without vomiting, may indicate pancreatitis. Right upper abdominal pain, fever, jaundice or pale stools may indicate gallbladder disease. Persistent vomiting with an inability to keep fluids down risks dehydration and acute kidney injury. Any of these warrant urgent medical assessment, not a message to a telehealth portal.
Tirzepatide carries a boxed warning for thyroid C-cell tumours based on rodent data. It is contraindicated if you or a family member has had medullary thyroid carcinoma or MEN 2.
Hair shedding
Reported in roughly 5–6% of trial participants at the highest dose. It is almost always telogen effluvium driven by the pace of weight loss rather than a direct drug effect, and it typically resolves. Slowing your rate of loss and keeping protein intake adequate are the practical levers.
Common questions
What dose of tirzepatide do most people end up on?
Most people settle between 7.5 mg and 12.5 mg. The efficacy gain from 10 mg to 15 mg was only about 1.4 percentage points in SURMOUNT-1, while side effects and often price continue to rise. Many people never need 15 mg.
Why do tirzepatide prices go up as my dose increases?
Because some programs price by dose tier rather than charging one rate. The advertised price usually reflects the 2.5 mg starter dose, which you occupy for about four weeks. Flat-rate programs charge the same amount at every dose. Over twelve months that structural difference typically matters more than any first-month discount.
What happens if I stop taking tirzepatide?
Weight regain is expected. In SURMOUNT-4, participants who switched to placebo after 36 weeks regained 14% of body weight over the following year, while those who continued lost a further 5.5%. Obesity behaves as a chronic condition and treatment is generally open-ended.
Is compounded tirzepatide legal in 2026?
Yes, when a state-licensed 503A pharmacy prepares it for an identified individual patient with a valid prescription. FDA declared the tirzepatide shortage resolved in December 2024, which ended mass compounding under shortage rules. Patient-specific compounding under section 503A of the Federal Food, Drug, and Cosmetic Act continues.
People also ask about tirzepatide side effects
What is tirzepatide side effects?
Tirzepatide side effects is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide side effects apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide side effects cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide side effects FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.